Phathom Pharmaceuticals, Inc.
PHATNasdaq
$10.94
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +31.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$897.6M
Enterprise Value
$880.4M
P/E
—
P/S
4.4
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-10.9%
Dividend Yield
—
Revenue (TTM)
$204.9M
Net Income (TTM)
$63.7M
Free Cash Flow (TTM)
-$97.8M
Gross Margin
84.9%
Operating Margin
-47.1%
Net Margin
31.1%
ROE
-18.9%
ROIC
—
Debt / Equity
-0.5
Net Cash
$17.2M
Return 1Y
+31.5%
Company profile
Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
- CEO
- Terrie Curran
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- New Jersey
- Website
- phathompharma.com
Management & directors
- Breedlove Robert CharlesPrincipal Accounting Officer
- Basta Steven LPresident and CEO
- Cook Anne MarieChief Legal Off. & Corp. Sec.
- Narula SanjeevChief Financial & Bus. Officer
Roles derived from SEC Form 4 filings.
Earnings
PHAT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$58.3M↑ +104.4%
Diluted EPS-$0.37↓ -71.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $682,000.00 | $55.3M | $175.1M |
| Gross profit | — | — | $0.00 | $515,000.00 | $47.3M | $152.5M |
| Operating income | -$125.7M | -$135.1M | -$172.4M | -$167.3M | -$277.5M | -$160.0M |
| Net income | -$129.1M | -$143.9M | -$197.7M | -$201,590.00 | -$334,330.00 | -$221,250.00 |
| Diluted EPS | — | -$3.89 | -$5.05 | -$3.93 | -$5.29 | -$3.03 |
| Operating cash flow | -$69.7M | -$148.5M | -$146.5M | -$137.6M | -$266.8M | -$166.8M |
| Free cash flow | -$70.7M | -$148.8M | -$147.6M | -$139.2M | -$266.9M | -$167.0M |
| Gross margin | — | — | — | 75.5% | 85.6% | 87.1% |
| Operating margin | — | — | — | -24532.6% | -502.2% | -91.4% |
| Net margin | — | — | — | -29.6% | -0.6% | -0.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $16.4M | $29.7M | $28.5M | $39.5M | $49.5M | $57.6M | $58.3M |
| Gross profit | $5.9M | $14.0M | $25.8M | $24.8M | $34.5M | $43.3M | $49.9M | $46.3M |
| Operating income | -$77.3M | -$70.8M | -$59.4M | -$78.9M | -$59.9M | -$15.3M | -$5.9M | -$15.5M |
| Net income | -$91.4M | -$85.6M | $259.5M | -$94.3M | -$75.8M | -$30.0M | $199.9M | -$30.4M |
| Diluted EPS | -$1.56 | -$1.32 | -$0.99 | -$1.31 | -$1.05 | -$0.41 | -$0.26 | -$0.37 |
| Operating cash flow | -$70.7M | -$63.6M | -$63.5M | -$84.9M | -$62.7M | -$14.1M | -$5.0M | -$15.6M |
| Free cash flow | -$70.8M | -$63.6M | -$63.5M | -$84.9M | -$62.8M | -$14.1M | -$5.1M | -$15.7M |
| Gross margin | 81.2% | 85.6% | 87.1% | 86.9% | 87.2% | 87.5% | 86.7% | 79.4% |
| Operating margin | -1055.4% | -433.0% | -200.3% | -276.5% | -151.7% | -30.8% | -10.3% | -26.5% |
| Net margin | -1248.6% | -523.3% | 874.9% | -330.7% | -191.9% | -60.5% | 347.1% | -52.1% |
Company news
May 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Breedlove Robert Charles· Principal Accounting Officer | Tax withholding | 1,555 | $11.04 | $17,159.43 | filing |
| 2026-05-22 | Parikh Asit | Gift | 28,000 | $0.00 | $0.00 | filing |
| 2026-05-22 | Parikh Asit | Gift | 28,000 | $0.00 | $0.00 | filing |
| 2026-05-20 | Parikh Asit | Option exercise | 17,500 | $4.95 | $86,625.00 | filing |
| 2026-05-19 | COLA MICHAEL F | Award | 24,122 | $0.00 | $0.00 | filing |
| 2026-05-19 | KARBE FRANK | Award | 24,122 | $0.00 | $0.00 | filing |
| 2026-05-19 | Schroeder Theodore R | Award | 24,122 | $0.00 | $0.00 | filing |
| 2026-05-19 | FIELDS HEIDI | Award | 24,122 | $0.00 | $0.00 | filing |
| 2026-05-19 | Parikh Asit | Award | 24,122 | $0.00 | $0.00 | filing |
| 2026-05-19 | Topper James N | Award | 24,122 | $0.00 | $0.00 | filing |
| 2026-05-19 | Stenhouse Mark | Award | 24,122 | $0.00 | $0.00 | filing |
| 2026-03-10 | Parikh Asit | Gift | 40,000 | $0.00 | $0.00 | filing |
| 2026-03-10 | Parikh Asit | Gift | 40,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | Breedlove Robert Charles· Principal Accounting Officer | Tax withholding | 964 | $12.56 | $12,107.84 | filing |
| 2026-02-27 | Breedlove Robert Charles· Principal Accounting Officer | Tax withholding | 414 | $12.56 | $5,199.84 | filing |
| 2026-02-27 | Breedlove Robert Charles· Principal Accounting Officer | Award | 2,790 | $0.00 | $0.00 | filing |
| 2026-02-27 | Breedlove Robert Charles· Principal Accounting Officer | Award | 13,000 | $0.00 | $0.00 | filing |
| 2026-02-10 | Basta Steven L· President and CEO | Tax withholding | 6,277 | $12.82 | $80,471.14 | filing |
| 2026-02-10 | Cook Anne Marie· Chief Legal Off. & Corp. Sec. | Tax withholding | 1,535 | $12.82 | $19,678.70 | filing |
| 2026-02-10 | Cook Anne Marie· Chief Legal Off. & Corp. Sec. | Award | 3,461 | $0.00 | $0.00 | filing |
| 2026-02-10 | Basta Steven L· President and CEO | Award | 12,362 | $0.00 | $0.00 | filing |
| 2026-01-23 | Parikh Asit | Gift | 80,500 | $0.00 | $0.00 | filing |
| 2026-01-23 | Parikh Asit | Gift | 80,500 | $0.00 | $0.00 | filing |
| 2026-01-21 | Breedlove Robert Charles· Principal Accounting Officer | Tax withholding | 776 | $13.61 | $10,561.36 | filing |
| 2026-01-13 | Parikh Asit | Option exercise | 8,750 | $10.30 | $90,125.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.